230 related articles for article (PubMed ID: 15956654)
21. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.
Linke SP; Bremer TM; Herold CD; Sauter G; Diamond C
Clin Cancer Res; 2006 Feb; 12(4):1175-83. PubMed ID: 16489071
[TBL] [Abstract][Full Text] [Related]
22. Identification of gene transcript signatures predictive for estrogen receptor and lymph node status using a stepwise forward selection artificial neural network modelling approach.
Lancashire LJ; Rees RC; Ball GR
Artif Intell Med; 2008 Jun; 43(2):99-111. PubMed ID: 18420392
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of independent gene expression microarray datasets improves the predictability of breast cancer outcome.
Zhang Z; Chen D; Fenstermacher DA
BMC Genomics; 2007 Sep; 8():331. PubMed ID: 17883867
[TBL] [Abstract][Full Text] [Related]
24. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
25. Tumor classification ranking from microarray data.
Hewett R; Kijsanayothin P
BMC Genomics; 2008 Sep; 9 Suppl 2(Suppl 2):S21. PubMed ID: 18831787
[TBL] [Abstract][Full Text] [Related]
26. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
27. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data.
Gui J; Li H
Bioinformatics; 2005 Jul; 21(13):3001-8. PubMed ID: 15814556
[TBL] [Abstract][Full Text] [Related]
28. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
[TBL] [Abstract][Full Text] [Related]
29. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
[TBL] [Abstract][Full Text] [Related]
30. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
[TBL] [Abstract][Full Text] [Related]
31. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
32. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
33. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
34. Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables.
Rouzier R; Coutant C; Lesieur B; Mazouni C; Incitti R; Natowicz R; Pusztai L
Breast Cancer Res Treat; 2009 Sep; 117(2):325-31. PubMed ID: 19152025
[TBL] [Abstract][Full Text] [Related]
35. Identification of differential gene expression for microarray data using recursive random forest.
Wu XY; Wu ZY; Li K
Chin Med J (Engl); 2008 Dec; 121(24):2492-6. PubMed ID: 19187584
[TBL] [Abstract][Full Text] [Related]
36. Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.
Vuaroqueaux V; Urban P; Labuhn M; Delorenzi M; Wirapati P; Benz CC; Flury R; Dieterich H; Spyratos F; Eppenberger U; Eppenberger-Castori S
Breast Cancer Res; 2007; 9(3):R33. PubMed ID: 17535433
[TBL] [Abstract][Full Text] [Related]
37. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
39. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.
Lee ES; Son DS; Kim SH; Lee J; Jo J; Han J; Kim H; Lee HJ; Choi HY; Jung Y; Park M; Lim YS; Kim K; Shim Y; Kim BC; Lee K; Huh N; Ko C; Park K; Lee JW; Choi YS; Kim J
Clin Cancer Res; 2008 Nov; 14(22):7397-404. PubMed ID: 19010856
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L
J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]